David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
Theravance Biopharma $100.5 million follow-on offering
We advised the underwriters on the equity offering
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Cyteir Therapeutics $133.2 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
RAPT Therapeutics $143.7 million follow-on offering
We advised the joint book-running managers on the SEC-registered equity offering
Ayala Pharmaceuticals $20 million at-the-market offering
We advised the sales agent on the stock offering
Charles River Laboratories acquisition of Vigene Biosciences
We are advising Charles River on the acquisition
AgileThought to combine with LIV Capital Acquisition Corp. and list on Nasdaq
We advised the SPAC on the transaction
ImmunityBio $500 million at-the-market offering
We advised the sales agent in connection with the equity offering